What CJC-1295 with DAC is, and what was actually measured in people

CJC-1295 is an analogue of growth-hormone-releasing hormone in its active 29-amino-acid form. Its defining feature is not that sequence but what is attached to it: a drug affinity complex — DAC — that binds permanently to the body's own albumin after injection [2].

The problem that complex solves is specific and well documented: natural GHRH has a half-life of minutes, and that is what always limited its use [1]. Bound to albumin, the molecule stops being cleared quickly.

What was measured, and in whom

Here the data are from people, not from animal models.

• Duration. In two randomised, double-blind, placebo-controlled ascending-dose trials lasting 28 and 49 days, the estimated half-life was 5.8 to 8.1 days [1].
• Growth hormone and IGF-I. After a single injection, mean growth hormone concentrations rose 2- to 10-fold for six days or more, and mean IGF-I 1.5- to 3-fold for nine to eleven days. With repeated doses, IGF-I stayed above baseline for up to 28 days [1].
• Secretion stayed pulsatile. This is a physiological detail that matters: much of growth hormone's effect is thought to depend on being released in pulses rather than continuously. A dedicated study confirmed that pulsatility persists under continuous stimulation by the analogue [2].
• Effect on the serum proteome. A third paper described changes in the serum protein profile of normal adults after activating the axis [3].

No serious adverse reactions were reported in the ascending-dose trials [1].

What those data are not

They are pharmacology, not clinical efficacy. The studies measured hormone concentrations in healthy adults, not outcomes: not body composition, not strength, not recovery, nothing long-term. Raising IGF-I is a laboratory result, not a demonstrated benefit.

There is no approved indication for CJC-1295 in the European Union or the United States, no phase 3 trials and no long-term safety data. A 2026 review places these compounds on an evidence scale running from randomised-trial data to a complete absence of human studies, and notes that uncertainty about product composition and about the protocols circulating online is part of the clinical problem [4].

This page describes published literature. It is not medical information, it does not describe a therapeutic use, and it does not replace any healthcare professional.

What to look at when comparing suppliers

• That it is the version with the drug affinity complex, stated explicitly. That is the difference between the molecule in these studies and a different one sold under an almost identical name.
• Identity confirmation by mass spectrometry for the batch: the complex changes the mass, so mass gives it away.
• HPLC purity for the specific batch, with a certificate you can read before buying.